Clinical Report: Airway Resistome Higher In Chronic Lung Disease
Overview
A recent study indicates that patients with chronic lung disease exhibit a higher prevalence of antimicrobial resistance genes in their lower airway microbiome compared to healthy controls. Notably, patients with sarcoidosis and idiopathic pulmonary fibrosis show the most significant differences.
Background
Understanding the airway resistome is crucial as it relates to the effectiveness of antibiotic treatments in chronic lung diseases. The presence of antimicrobial resistance genes can complicate management strategies and influence patient outcomes. This study highlights the potential impact of antibiotic exposure and the underlying microbiome in chronic lung disease.
Data Highlights
| Condition | Prevalence of Resistance Genes |
|---|---|
| Healthy Controls | 38% |
| Asthma | 39% |
| COPD | 51% |
| Sarcoidosis | 65% |
| IPF | 83% |
Key Findings
- 33% of samples contained tetracycline resistance genes.
- Patients with sarcoidosis had 3.5 times higher odds of harboring resistance genes compared to controls.
- Patients with IPF had 6.4 times higher odds of harboring resistance genes compared to controls.
- Recent antibiotic exposure was linked to a higher burden of resistance genes.
- Subgroup analyses indicated increased risk of tetracycline resistance in COPD patients with multiple exacerbations.
Clinical Implications
Healthcare professionals should be aware of the increased prevalence of antimicrobial resistance genes in patients with chronic lung diseases, particularly those with sarcoidosis and IPF. This knowledge can guide antibiotic stewardship and management strategies to mitigate the risk of treatment failure.
Conclusion
The findings underscore the importance of monitoring antimicrobial resistance in chronic lung disease patients, particularly in the context of antibiotic use and its implications for treatment outcomes.
References
- Kringeland G. D., BMJ Open Respiratory Research, 2026 -- Airway Resistome Higher In Chronic Lung Disease
- Frontiers in Immunology, 2026 -- Microbiome-innate immune crosstalk in acute exacerbation of idiopathic pulmonary fibrosis: an amplification framework
- Infection, 2022 -- The Range of Aspergillosis Manifestations in Patients with Chronic Obstructive Pulmonary Disease
- The Journal of Infectious Diseases, 2022 -- The Role of Microbiota, Mucus, and Therapeutic Modulators in the Pathogenesis of Infections in Cystic Fibrosis During the Era of CFTR Modulator Treatments
- conexiant — Viral, Fungal Infections May Contribute to Nonresolving ARDS
- Antimicrobial resistance genes and antibiotic use in chronic lung disease: a bronchoscopy study of the lower airways microbiome - PMC
- Acute exacerbation of chronic obstructive pulmonary disease - Treatment algorithm | BMJ Best Practice US
- Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline - PMC
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
